At-Home Genetic Testing Goes Beyond Just DNA
TechTalk looks at 23andMe’s DNA test-taking kit and its recent approval by the FDA to scan for certain breast cancer genes. We examine the possibilities and limitations, where the market is headed, and what it means for the biotech industry and its business advisors.
Dave Plaskow: Hello and welcome to EisnerAmper’s technology podcast series. With more than 500 technology clients, we’re always interested in the latest industry trends and developments as well as any related business and accounting opportunities and challenges. I’m your host Dave Plaskow and with us today is Dave Katz, Senior Manager in EisnerAmper’s Technology and Life Sciences Practice. It’s another episode of TechTalk. Today’s episode is on a mail-in DNA kit that can screen for breast cancer genes. Hi Dave.
Dave Katz: Hi Dave, how are you?
DP: Good. So last time we spoke we talked about the Apple Watch accessory that can act as an EKG. So now the 23andMe, that mail-in DNA test-taking-kit company (there’s a few of them out there) but the kit can actually tell customers about three mutations in the breast cancer genes BRCA1 and BRCA2. Now these are a couple of consumer-based products that the FDA has really had a hand in repositioning.
DK: Correct. The trend has been increased access to health care information. 23andMe received FDA authorization on carrier test for Bloom Syndrome in 2015 and risk report for several conditions such as Parkinson’s and Alzheimer’s in 2017. Industry people have called it the continued march of the democratization of health care.
DP:What’s the down side here?
DK: So 23andMe only tests for three mutations in BRCA1 and one in BRCA2. These mutations are among the most common and best studied but they still account for only a fraction of hereditary breast cancers in the U. S. There are more 1,000 known BRCA mutations, some of which are linked to increased cancer risk, some of which aren’t, others whose risk is unknown. So the test doesn’t cast a very wide net, and it’s certainly not a replacement for regular visits to your physician.
DP:What are we talking about here in dollars and cents?
DK: A variety of companies offer kits that cost anywhere from $99 to $199 each. The global consumer genetic testing market was $70 million in 2015 and is expected to be $340 million by 2022.
DP:That’s almost a fivefold increase. So how might something like this, what we talked about as far as the increased access to health care information, how can this impact the life science and biotech sector as well as impact people like you who provide business consulting services?
DK: Anytime a company can move through FDA approval, it’s good for the industry. It challenges other companies; it shows the willingness of the FDA to accept newer methods of testing. So we should see continued investing and funding in the industry, and with that comes the need for qualified business partners to be there every step of the way.
DP:Great. Dave, thanks for your expertise here.
DK: Thanks Dave.
DP:And thank you for listening to another episode of TechTalk, as part of the EisnerAmper podcast series. Visit EisnerAmper.com for more information on this, and a host of other topics. And join us for our next EisnerAmper podcast when we get down to business.
EisnerAmper’s Technology and Life Sciences practice talks about the Theranos dissolution, and what took them from biotech unicorn to dissolution. Investors must use due diligence and consider a company's internal controls before investing in companies with high valuations.
EisnerAmper's Technology podcast series discusses the proposed New York City Council cap on the number of ridesharing vehicles such as Lyft and Uber in Manhattan to ease congestion. How will this cap change Uber's valuation, and what is the economic hit to the taxi industry?
This episode of the Dave & Dave Show discusses new cryptocurrency technology from the fintech startup company Circle, called USD Coin. This cryptocurrency ties itself to the U.S. Dollar, therefore eliminates some volatility that comes with crypto mining and Bitcoin.
TechTalk takes a look at a tech startup, Aerobotics, that is using drones to help farmers in South Africa. This podcast discusses how the drones help South African farmers, how the US government is using drones and how MIT is making micro drones.
TechTalk discusses a new 3d printed community proposed in El Salvador by the nonprofit New Story and ICON construction. Icon and New Story debuted their 3D printed house at the Austin South by Southwest festival. Issues discussed include cybersecurity and valuation.
TechTalk examines Jeff Bezos' new possible Amazon facility cities of Austin, New York City, Washington DC and Atlanta, with Atlanta being Dave Katz' first pick. They also discuss Amazon Go, and Amazon's healthcare initiative with Berkshire Hathaway.
EisnerAmper’s technology podcast discusses the first FDA approved EKG band for the Apple Watch. Dave Katz of the Technology and Life Sciences practice discuses these new medical devices, their use of artificial intelligence and the cybersecurity issues surrounding them.
EisnerAmper’s technology podcast discusses related business and accounting opportunities with the senior manager in its Technology and Life Sciences practice about Uber, drones, internet providers and net neutrality, IPOs, AI and the R&D credit that may expire next year.
Is AI Destined to Replace Fund Managers? This episode of TechTalk talks about the first ETF powered by artificial intelligence (AI), the technology behind it, if it impacts a fund’s expense ratio and, most importantly, how it’s performing.
It was a milestone when Facebook implemented facial recognition software in 2010. The iPhone X has put a renewed spotlight on facial recognition technology. EisnerAmper’s Technology and Life Sciences Manager discusses security issues surrounding facial recognition technology.
Supersonic air travel is coming back with a boom. What does today’s market look like for supersonic air travel and how are start-ups such as Boom and Aerion navigating the many challenges? Also discussed is mergers and acquisitions and the need for valuations.
Is iRobot’s Roomba automated vacuum collecting consumer data that will be offered to technology companies to enhance internet of things devices? Here is what information is being collected, potential data privacy and security issues, and iRobot’s response to consumer concerns.
Tesla has received a significant investment from Chinese tech giant Tencent. This podcast discusses what Tesla plans to do with the cash infusion, Tencent’s ownership stake and how this could help both companies enter the highly coveted self-driving car market.
Amazon’s CEO Jeff Bazos just passed Warren Buffet to become the second wealthiest person on the planet. In Technology M&A news, Amazon competes with Alibaba by buying Dubai based Souq in a battle over E-commerce in the middle east, as reported by EisnerAmper’s Life Sciences Practice.
With retiring baby boomers some of the fastest growing jobs in technology attracting tech talent are located in New York City, San Francisco, Austin and Seattle. Tech talent can come from non-traditional backgrounds and there is strong hiring growth in hubs such as New York City.
Amazon Go wants to streamline your grocery shopping. This podcast discusses Amazon’s plan to use 'Just Walk Out Technology' to change food shopping. A look at the technology behind Amazon Go, potential speedbumps and what it could mean for bricks-and-mortar grocery chains.
David in EisnerAmper’s Technology and Life Sciences Practice, gives a “state of the union” on self-driving cars, an overview of Uber’s unique experiment in Pittsburgh, and a glimpse of what we can expect in the marketplace over the next few years.
This episode of TechTalk we discuss the commercial real estate shortage for the nation’s biotech sector. Life science and biotech companies in hubs like Boston and San Fran are seeking out real estate in the suburbs in order to afford space to expand their businesses.
This Life Sciences and Technology podcast talks about the space-age technology called the Hyperloop. The Hyperloop could take people from LA to San Francisco in 35 minutes, and was originally conceived by Elon Musk. Hyperloop One is the first company to develop the technology.
David discusses the commercial drone market, including how the FAA will regulate pilot licenses, drone use in real estate, Amazon's use of drones for future deliveries, the VC market and M&A strategies for companies interested in investing in drone technology.
David discusses virtual reality including Facebook's acquisition of Oculus, HTC's Vive and revenue recognition that comes from virtual reality technology. HTC has created the Vive X Fund and Facebook has created a similar fund to help develop virtual reality software.